$0.01
(Market cap
$123 Mln
Revenue (TTM)
$80 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-9 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
27.76
-
EV/EBITDA
16.4
-
Debt to Equity
2.4
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
56,424,200
10 Years Aggregate
CFO
$-74.38 Mln
EBITDA
$-99.01 Mln
Net Profit
$-234.10 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Recro Pharma Inc (REPH)
| -53.8 | -43.6 | -49.0 | -68.5 | -54.4 | -36.5 | -- |
|
BSE Sensex*
| -10.8 | -3.8 | -8.5 | -8.0 | 6.9 | 8.6 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Recro Pharma Inc (REPH)
| -40.0 | -84.5 | 187.9 | -23.1 | 14.8 | -10.4 | 214.7 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Recro Pharma Inc (REPH)
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and... internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania. Read more
-
Pres, CEO & Director
Mr. J. David Enloe Jr.
-
Pres, CEO & Director
Mr. J. David Enloe Jr.
-
Headquarters
Exton, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Recro Pharma Inc (REPH)
What is the current share price of Recro Pharma Inc (REPH) Today?
The share price of Recro Pharma Inc (REPH) is $0.79 (NASDAQ) as of 23-May-2022 09:30 EDT. Recro Pharma Inc (REPH) has given a return of -54.43% in the last 3 years.
What is the current PB & PE ratio of Recro Pharma Inc (REPH)?
Since, TTM earnings of Recro Pharma Inc (REPH) is negative, P/E ratio is not available.
The P/B ratio of Recro Pharma Inc (REPH) is 2.55 times as on 23-May-2022, a 58 discount to its peers’ median range of 6.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Recro Pharma Inc (REPH)?
The 52-week high and low of Recro Pharma Inc (REPH) are Rs -- and Rs -- as of 20-May-2026.
What is the market cap of Recro Pharma Inc (REPH)?
Recro Pharma Inc (REPH) has a market capitalisation of $ 123 Mln as on 23-May-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Recro Pharma Inc (REPH)?
Before investing in Recro Pharma Inc (REPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.